OP
The startup develops a topical drug therapy for onychomycosis using a bioactive extract from the cyanobacteria strain Arthrospira maxima, which exhibits natural anti-fungal properties. This patented processing application achieves a high mycological and clinical cure rate without treatment-related adverse effects, providing an effective solution for nail fungus.
Updated 3 months ago
Funding
$960K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a topical drug therapy for onychomycosis using a bioactive extract from the cyanobacteria strain Arthrospira maxima, which exhibits natural anti-fungal properties. This patented processing application achieves a high mycological and clinical cure rate without treatment-related adverse effects, providing an effective solution for nail fungus.